leadf
logo-loader
viewIXICO PLC

IXICO Plc chief hugely excited by 'really big growth opportunities'

IXICO chief executive Derek Hill caught up with Proactive to discuss the company's full year results and new partnerships.

Hill tells Proactive: We're very focused on the brain. Neurodegenerative diseases have been our longer term focus - the perhaps best known one of those - Alzheimer's Disease which is the main cause of dementia.''

''Traditionally IXICO has, for the last 12 years, been working with pharmaceutical companies supporting them in developing drugs, particularly for neurodegenerative diseases ... but recently we've also got some of our technology crossing over from the world of developing drugs into being used alongside drugs in the clinics''.

''We're using technology that we have for many years been applying to support pharmaceutical companies developing drugs. We're now using that to help make those drugs safer when used with patients in the clinic once they're marketed'', Hill added.

Hill went on to say: ''We are involved in several European projects which are collaborations with the pharmaceutical industry but also with major academic centres across Europe'''.

Quick facts: IXICO PLC

Price: 118.5 GBX

AIM:IXI
Market: AIM
Market Cap: £55.8 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of IXICO PLC named herein, including the promotion by the Company of IXICO PLC in any Content on the Site, the Company receives from said issuer...

FOR OUR FULL DISCLAIMER CLICK HERE

IXICO plays 'pivotal role' after announcing £2m extension to Huntington's...

IXICO PLC's (LON:IXI) Lammert Albers talks to Proactive London about the £2m extension to a contract to provide additional imaging services for a pivotal Huntington's disease (HD) study. Albers describes this as a 'strong suit' having started very early and now carrying out a Phase III...

on 09/29/2020

2 min read